Tirabrutinib

1 abstract

Abstract
Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.
Org: Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China, Osaka International Cancer Institute, Osaka, Japan, Department of Neurosurgery and Neuro-Oncology, National Cancer Center Research Institute, Tokyo, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Kyorin University Faculty of Medicine,